BioSpace News Archive

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 second-quarter conference call on Wednesday, February 5, 2020, at 3:30 p.m. CT (4:30 p.m. ET)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided 2019 highlights and 2020 guidance and priorities at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

LifeSignals Inc., a global leader in the field of wireless biosensor technology through the Life Signal™ Processor silicon platform, announced its merger with the connected health assets of Renew Health Limited (Renew), based in Ireland and Singapore.

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that it has dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with the Tn/STn glycoform of mucin 1 (TnMUC1) chimeric antigen receptor T-cell (CAR-T) therapy in patients with TnMUC1-positive advanced cancers.

Bristol-Myers Squibb Company (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations

NuMedii, Inc. today announced a new partnership with a drug delivery company to develop new therapeutics for ulcerative colitis

Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020, to discuss the recently announced licensing agreement with Bayer and Daré’s broader partnering strategy, and to provide a general corporate update.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has completed dosing the last patient in the registration-enabling Cohort 4 of the C-144-01 study of lifileucel in the treatment of patients with advanced melanoma

Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that the United States Adopted Names Council (USAN) of the American Medical Association has approved the use of ibezapolstat

Emboline™, Inc., developer of total embolic protection technology for transcatheter aortic valve replacement (TAVR), today announced completion of enrollment in its SafePass™ 2 clinical study of the Emboliner™ Embolic Protection Catheter.